Elizabeth Davis – Corporate Relations A. J. Kazimi – Chief Executive Officer Martin E. Cearnal – Chief Commercial Officer and Senior Vice President Rick S. Greene – Chief Financial Officer and Vice President-Finance and Accounting

Good afternoon, ladies and gentlemen. And welcome to Cumberland Pharmaceutical’s Fourth Quarter 2013 Earnings Conference Call. During the Company’s presentation all parties will be in a listen-only mode. Following the presentation, conference will be opened for questions. This call is being recorded and a replay will be available for one week, shortly following its conclusion. At this time, I’d like to turn the call over to Elizabeth Davis who handles, Corporate Relations for Cumberland Pharmaceuticals. Please go ahead.

Hello, everyone. Today we issued a press release featuring our fourth quarter 2013 financial results and company updates. If you have not seen our press release issued today, you can access it on our website at www.cumberlandpharma com. Before we begin, we would like to advise you that this call will include forward-looking statements, which reflect our current views about future events. Such forward-looking statements are subject to risks outlined in the Safe Harbor section of today's press release and are detailed in our 10-K and 10-Q reports on file with SEC. Despite our best efforts, actual results could differ materially from our expectations. Information shared on the call today should be considered current as of today only, and please remember that the Company assumes no duty to update it. We post and maintain the current version of our corporate presentation as well as other press releases and company updates on the Investors portion of our website. Also, please note that this conference call is being webcast through our website and will be available there. I’ll now turn the call over to our Chief Executive Officer, A. J. Kazimi.

Thanks Elizabeth, good afternoon everyone, and thank you for joining us, as we review our 2013 results and discuss our strategy for 2014. With me on today’s call are Cumberland’s Commercial Officer, Marty Cearnal and our Chief Financial Officer, Rick Greene. We’ll start by reviewing 2013 and to recent developments and then provide an update on our products, followed by a discussion of our financial performance for the year. Finally, we’ll outline our strategy for 2014, before opening the call to any questions. So let’s begin. If you’ve been following the Company over the past year you’re well aware that 2013 brought new challenges, testing the entire Cumberland organization. I’m pleased to report that our team rose to the occasion and has never been more energized. The Company was faced with the decision you see on whether to change strategy, given the FDA’s approval of a generic competitor to our Acetadote product. Should we preserve our corporate infrastructure or enact significant expense reductions to maintain profitability which could jeopardize our development and commercial capabilities. Given our ability to respond to the challenges the potential of our marketed and pipeline products as well as our financial strength, we determine that staying the course with the best approach for building the future value of our company. We developed a company wide action plan, with specific objectives that have been successfully executing them. We did not standstill when Acetadote our largest revenue product came under generic competition. We deployed a counter measure strategy in a timely highly fashion. We quickly launched our authorized generic to Perrigo company in order to also participate in the generic segment of the market. And as a reminder, both Acetadote and our authorized generic contain our new formulation which is free of any preservatives, stabilizing or chelating agents.…

Thank you, A.J. Let’s begin with our newest products; Vaprisol and Omeclamox-Pak. We are excited about the addition of Vaprisol, our newest injectable hospital product. As A.J. mentioned, that’s used in hyponatremia in the hospital critical care setting. Vaprisol has been commercially available since 2006, but it’s not been actively promoted since 2012. Our first order of business will be to seamlessly transfer the commercial supply, distribution and medical support of the product to ensure no disruption in the marketplace. Meanwhile, we are beginning preparations to relaunch active promotion by our hospital sales force during the first half of the year. Then we will build upon this initial experience and fine-tune our sales and marketing activities to highlight those product attributes that resonate with prescribers and support our efforts to grow this new brand. These products overlays well with our existing calling efforts with the hospital sales force, which will feature Vaprisol along side our Caldolor and Acetadote brands. Our second new products is Omeclamox-Pak. We launched our commercial efforts to promote this brand in January. Cumberland promotes the product to gastroenterologists across the United States through our field sales force, which also promotes our Kristalose brand. As you may know, many stomach ulcers are caused by an infection from the bacteria Helicobacter pylori or H. pylori, which colonize in the stomach and duodenum. When present, this bacterial infection has been proven to be the cause of over 90% of duodenal ulcers. These ulcers commonly cause abdominal pain and may lead to serious bleeding. In the United States the prevalence of H. pylori is approximately 30% to 40% in adults and its eradication has been shown to reduce the risk of duodenal ulcer reoccurrence. Omeclamox-Pak is a branded prescription product that combines three key ingredients; omeprazole, amoxicillin and clarithromycin for…

Thank you, Marty. For the full year ended December 31, 2013, Cumberland’s net revenues were $32 million compared to $48.9 million in the prior year. Net revenue for Acetadote in 2013 was $80.8 million compared to $37.5 million in 2012. Acetadote revenue included $9.2 million from our authorized generic in 2013 compared to $0.3 million in 2012. Net revenue for Kristalose in 2013 was $9.1 million, similar to the prior year. Net revenue for Caldolor in 2013 was $2.1 million, more than doubling the prior year sales. Our newest product, Omeclamox-Pak, contributed $1 million of revenue in 2013. During the fourth quarter of 2013, net revenues were $8.1 million, down from $13.7 million during the corresponding period in 2012. For the three months ended December 31, 2013, net revenues were $3.7 million for Acetadote, including $2.2 million from our authorized generic, $2.8 million for Kristalose, $1 million for Omeclamox-Pak and $600,000 for Caldolor. For the year ended December 31, 2013, our total operating expenses were $35.8 million compared to $40 million for 2012. Total operating expenses for the three months ended December 31, 2013 were $10.6 million compared to $10.4 million for the prior year period. We ended 2013 with a net loss of $2.2 million, compared to net income of $5.8 million in 2012. The net loss for the fourth quarter was $1.5 million, compared to net income of $1.8 million for the same period in 2012. Diluted loss per share for the year ended December 31, 2013, was $0.11, compared to earnings per share of $0.30 for 2012. Diluted loss per share for the fourth quarter was $0.08, compared $0.09 in earnings for the fourth quarter of 2012. At the end of the year we had $54.9 million in cash reserves, which included cash, cash equivalents and marketable securities. Total assets at December 31, 2013, were $87.6 million, compared to $98.6 million at the end of 2012. We were cash flow positive from operations during 2013. During the year we used cash to pay off our line of credit, invest NOIs for Omeclamox-Pak, fund our Acetadote defense, patent defense and continue our share repurchase program. During 2013, we actively repurchased Cumberland shares and have now bought back a total of 3.5 million shares since we launched the initiative in 2010. That completes the financial report for both the full year and the fourth quarter of 2013. I’ll turn it back over to you, A. J.

Thanks, Rick. I’d like to take a brief moment to summarize our strategic focus for 2014 as we managed the company in a way to maximize the next phase of Cumberland’s growth. Our plan for 2014 is to continue to build a diversified specialty product portfolio while deploying our resources to sustain long-term profitability. We’re very optimistic about the opportunities that Vaprisol and Omeclamox-Pak will offer Cumberland. Our sales organization is enthusiastic about promoting both of these products. Our company will continue to monitor market conditions and fully support our Caldolor, Kristalose and Acetadote brands. We’ll focus our development efforts on accelerating our pipeline candidates while also advancing new clinical programs. We will conclude the analysis, reports and publications for the completed Caldolor study and update the comprehensive safety and efficacy data set for that product. We plan to continue expansion of our international activities through selectively chosen partners and will organize our manufacturing network in order to establish an uninterrupted supply of high quality products. We want to maintain our new momentum in business development and continue to pursue additional opportunities to acquire new commercial or late-stage development products. Management remains committed to maintaining a strong balance sheet, returning the company to profitability and placing revenues back on the growth trajectory. We do expect to return the company to profitability for the full year 2014. We believe our stock represents an attractive investment opportunity and we’ll continue repurchasing shares with excess cash. So in closing, while we faced new challenges in 2013, we emerged here in 2014 with a leaner, more diversified company, powered by an outstanding team of individuals throughout this organization and I would like to take this opportunity to thank each of them for their dedicated efforts and many contributions. The interest of this organization, its management and our shareholders remain closely aligned. We’ll continue to focus on our mission of improving patient care through the delivery of high quality pharmaceutical products. With that, let’s open the call to any questions. Operator, please proceed.

Thank you, sir. Ladies and gentlemen, that concludes the company’s presentation. We’ll now call for questions. (Operator Instructions) And I see no questions at this time. I would like to turn the call back over to management for any closing remarks.

Okay. I just want to everyone for joining our call today. We do appreciate your time and interest in Cumberland and we look forward to providing with another update following the close of the first quarter.

Thank you, sir. Ladies and gentlemen, that concludes our conference for today. If you would like to listen to a phone replay of today’s conference, please dial 855-859-2056, using the access code 24879662, through August 2014. Alternatively, a replay of the webcast will be available on the company’s Investor Relations website. I would like to thank you for your participation. You may now disconnect.